Outcomes following SARS-CoV-2 infection in liver transplant recipients: An international registry study

By Webb GJ, Marjot T, Cook JA, et al.
Published August 29, 2020

Key Takeaways

Researchers investigated the clinical outcomes in patients with laboratory-confirmed SARS-CoV-2 infection, who were older than 18 years, who had previously received a liver transplant. Assessing data submitted by clinicians to one of two international registries (COVID-Hep and SECURE-Cirrhosis) at the end of the patient's disease course, they collected data for 151 adult liver transplant recipients from 18 countries (median age 60 years, 102 [68%] men, 49 [32%] women) and 627 patients who had not undergone liver transplantation (median age 73 years, 329 [52%] men, 298 [48%] women). Regarding the proportion of patients hospitalized or who required intensive care, there was no difference between the groups, though, in the liver transplant cohort, ICU admission and invasive ventilation were seen more often. Analysis revealed mortality among these cases had independent correlation with higher age and presence of comorbidities, but not with liver transplantation. They emphasize preferentially considering factors other than transplantation relative to physical distancing and medical care for patients with liver transplants during the COVID-19 pandemic.

Read the full article on The Lancet: Gastroenterology & Hepatology.

Share with emailShare to FacebookShare to LinkedInShare to Twitter